Prot #PCYC-1121-CA: A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date4/24/143/31/18

Funding

  • PRA Health Sciences (Prot #PCYC-1121-CA)
  • Pharmacyclics, Inc. (Prot #PCYC-1121-CA)